Andrew Rees, MD
Interventional Cardiology · Baton Rouge, LANPI 1932174166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 11.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for interventional cardiology clinicians in LA, where the typical reported total is $9,970.
Across 219 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$442
- Amgen$429
- Johnson & Johnson$427
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$366
- Pfizer$336
- Actelion Pharmaceuticals US, Inc.$300
- plus $2K from 23 others
Across 3 payments — averaging $30,384 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$91K
What the payments were for
- Food & beverage$3,90099%
- Education$80%
- Other$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $442 |
| Amgen | 27 | $429 |
| Johnson & Johnson | 28 | $427 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $366 |
| Pfizer | 20 | $336 |
| Actelion Pharmaceuticals US, Inc. | 9 | $300 |
| E.r. Squibb & Sons, L.L.C. | 17 | $248 |
| Alnylam Pharmaceuticals Inc. | 8 | $203 |
| Boehringer Ingelheim | 9 | $167 |
| Medtronic | 2 | $124 |
| Merck | 6 | $114 |
| Bayer | 5 | $99 |
| Baxter Healthcare | 3 | $85 |
| AstraZeneca | 5 | $82 |
| Akcea Therapeutics, Inc. | 2 | $55 |
| Esperion Therapeutics, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Cleerly, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 2 | $49 |
| Kestra Medical Technology Services, Inc. | 2 | $36 |
| Abiomed | 2 | $34 |
| Grifols USA, LLC | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Itamar Medical Inc | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
How this compares
$3,925 in reported general payments places this provider in the 20th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 250 | $236,183 |
| EntrestoSacubitril/Valsartan | 190 | $161,186 |
| XareltoRivaroxaban | 69 | $67,193 |
| Repatha SureclickEvolocumab | 85 | $65,790 |
| JardianceEmpagliflozin | 53 | $48,017 |
| NexlizetBempedoic Acid/Ezetimibe | 24 | $13,606 |
| Metoprolol Succinate | 329 | $3,695 |
| Atorvastatin Calcium | 257 | $3,450 |
| Nebivolol Hcl | 43 | $2,429 |
| Rosuvastatin Calcium | 160 | $2,347 |
| Ezetimibe | 83 | $1,972 |
| Digoxin | 34 | $1,928 |
| Pravastatin Sodium | 70 | $1,211 |
| Olmesartan Medoxomil | 65 | $1,047 |
| Carvedilol | 150 | $984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $336 | $236,183250 claims |
| NovartisEntresto | $442 | $161,186190 claims |
| Johnson & JohnsonXarelto | $427 | $67,19369 claims |
| Boehringer IngelheimJardiance | $167 | $48,01753 claims |
| Esperion Therapeutics, Inc.Nexlizet | $52 | $13,60624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$901K
- Jorge CastellanosBaton Rouge$185K
- Venkata GadiBaton Rouge$117K
- Steven KelleyBaton Rouge$116K
- Garland GreenBaton Rouge$37K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Daniel FontenotBaton Rouge$16K
- Amit PatelBaton Rouge$16K
- Craig WalkerHouma$5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.